See more : Capital & Regional Plc (CAL.L) Income Statement Analysis – Financial Results
Complete financial analysis of Exelixis, Inc. (EXEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Exelixis, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Hanatour Japan Co., Ltd. (6561.T) Income Statement Analysis – Financial Results
- The Steel Public Company Limited (THE.BK) Income Statement Analysis – Financial Results
- Pearl Holdings Acquisition Corp (PRLHW) Income Statement Analysis – Financial Results
- Pharmaniaga Berhad (7081.KL) Income Statement Analysis – Financial Results
- Multi Manager Invest Globale Value Aktier (MMIGLVAAKTAKK.CO) Income Statement Analysis – Financial Results
Exelixis, Inc. (EXEL)
About Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.83B | 1.61B | 1.43B | 987.54M | 967.78M | 853.83M | 452.48M | 191.45M | 37.17M | 25.11M | 31.34M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.47M | 98.67M | 75.96M | 52.86M | 51.54M | 44.32M | 41.01M | 24.76M | 10.50M | 2.27M |
| Cost of Revenue | 72.55M | 57.91M | 52.87M | 36.27M | 33.10M | 26.35M | 15.07M | 6.55M | 3.90M | 2.04M | 1.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 202.00K | 820.00K | 1.09M | 779.00K | 0.00 | 0.00 | 0.00 | -18.60M | -5.70M | 0.00 |
| Gross Profit | 1.76B | 1.55B | 1.38B | 951.27M | 934.68M | 827.48M | 437.41M | 184.90M | 33.28M | 23.07M | 30.22M | 47.45M | 289.64M | 185.05M | 151.76M | 117.86M | 113.27M | 97.85M | 74.88M | 52.08M | 51.54M | 44.32M | 41.01M | 43.36M | 16.20M | 2.27M |
| Gross Profit Ratio | 96.04% | 96.41% | 96.32% | 96.33% | 96.58% | 96.91% | 96.67% | 96.58% | 89.52% | 91.86% | 96.43% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 99.82% | 99.17% | 98.57% | 98.53% | 100.00% | 100.00% | 100.00% | 175.11% | 154.29% | 100.00% |
| Research & Development | 1.04B | 891.81M | 693.72M | 547.85M | 336.96M | 182.26M | 112.17M | 95.97M | 96.35M | 189.10M | 178.76M | 128.88M | 156.84M | 210.68M | 234.70M | 257.39M | 225.38M | 185.48M | 141.14M | 137.72M | 127.62M | 112.01M | 82.70M | 48.46M | 21.70M | 12.10M |
| General & Administrative | 502.71M | 418.26M | 369.92M | 268.26M | 210.34M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 0.00 | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 40.00M | 41.60M | 31.80M | 25.10M | 17.90M | 14.80M | 8.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 542.71M | 459.86M | 401.72M | 293.36M | 228.24M | 206.37M | 159.36M | 116.15M | 57.31M | 50.83M | 50.96M | 31.84M | 33.13M | 33.02M | 38.96M | 36.89M | 44.94M | 39.12M | 27.73M | 20.91M | 18.59M | 18.76M | 19.17M | 18.91M | 7.60M | 5.47M |
| Other Expenses | 0.00 | -197.00K | -184.00K | 912.00K | 680.00K | 397.00K | -3.54M | 7.47M | 0.00 | 9.64M | 2.35M | 9.17M | 10.14M | 32.74M | 0.00 | 41.46M | 82.08M | 39.94M | 28.82M | 21.68M | 19.25M | 19.42M | 26.95M | 37.76M | 13.30M | 5.47M |
| Operating Expenses | 1.59B | 1.35B | 1.10B | 841.21M | 565.21M | 388.62M | 271.53M | 212.11M | 153.66M | 239.93M | 229.72M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 86.22M | 35.00M | 17.57M |
| Cost & Expenses | 1.66B | 1.41B | 1.15B | 877.48M | 598.31M | 414.97M | 286.60M | 218.66M | 157.55M | 241.97M | 230.84M | 160.72M | 189.97M | 243.70M | 273.67M | 298.85M | 307.45M | 225.42M | 169.95M | 159.41M | 146.87M | 131.44M | 109.65M | 67.62M | 29.30M | 17.57M |
| Interest Income | 86.54M | 33.07M | 7.67M | 19.87M | 27.96M | 12.84M | 4.88M | 4.86M | 412.00K | 4.34M | 1.22M | 1.99M | 1.46M | 138.00K | 1.51M | 5.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 33.06M | 48.67M | 48.61M | 45.35M | 27.09M | 16.26M | 9.34M | 12.67M | 6.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 25.72M | 20.88M | 13.63M | 13.97M | 11.17M | 7.77M | 1.19M | 1.00M | 1.41M | 2.39M | 3.15M | 5.72M | 6.82M | 10.54M | 12.60M | 13.23M | 11.33M | 16.91M | 17.76M | 17.49M | 17.75M | 16.70M | 15.21M | 18.86M | 5.70M | 0.00 |
| EBITDA | 196.60M | 222.36M | 300.30M | 110.06M | 369.47M | 438.86M | 168.30M | -36.16M | -119.60M | -217.73M | -196.36M | -114.73M | 100.07M | -72.52M | -115.58M | -155.58M | -157.05M | -109.84M | -70.87M | -89.06M | -77.59M | -70.41M | -53.43M | -24.01M | -13.10M | -15.30M |
| EBITDA Ratio | 10.74% | 12.51% | 19.98% | 11.14% | 38.18% | 52.95% | 36.96% | -11.67% | -322.73% | -846.33% | -632.71% | -222.47% | 34.92% | -25.92% | -79.33% | -143.77% | -193.52% | -111.32% | -100.36% | -114.48% | -149.90% | -157.86% | -107.47% | 56.90% | -124.76% | -673.24% |
| Operating Income | 170.89M | 201.48M | 286.67M | 110.06M | 369.47M | 438.86M | 165.91M | -28.12M | -121.42M | -224.46M | -200.73M | -122.44M | 89.54M | -91.40M | -121.91M | -179.31M | -157.05M | -126.75M | -93.99M | -135.20M | -96.26M | -87.82M | -75.31M | -42.86M | -18.80M | -15.30M |
| Operating Income Ratio | 9.34% | 12.51% | 19.98% | 11.14% | 38.18% | 51.40% | 36.67% | -14.69% | -326.65% | -893.86% | -640.54% | -258.03% | 30.91% | -49.39% | -80.33% | -152.14% | -138.40% | -128.46% | -123.74% | -255.79% | -186.77% | -198.15% | -183.67% | -173.12% | -179.05% | -673.24% |
| Total Other Income/Expenses | 86.64M | 32.87M | 7.49M | 20.78M | 28.64M | 13.24M | -7.33M | -42.10M | -40.27M | -44.27M | -44.12M | -25.10M | -12.54M | -1.01M | -18.94M | 3.74M | 46.03M | 25.26M | -819.00K | -2.04M | 1.14M | 3.29M | -9.36M | -38.09M | 0.00 | -370.00K |
| Income Before Tax | 257.52M | 234.35M | 294.15M | 130.84M | 398.11M | 452.09M | 158.58M | -70.22M | -169.68M | -268.72M | -244.86M | -147.54M | 76.99M | -92.40M | -140.84M | -162.85M | -86.38M | -101.49M | -94.81M | -137.25M | -95.12M | -84.53M | -84.68M | -80.96M | 0.00 | -15.67M |
| Income Before Tax Ratio | 14.07% | 14.55% | 20.50% | 13.25% | 41.14% | 52.95% | 35.05% | -36.68% | -456.48% | -1,070.14% | -781.34% | -310.93% | 26.58% | -49.93% | -92.81% | -138.18% | -76.13% | -102.86% | -124.81% | -259.65% | -184.55% | -190.73% | -206.50% | -326.98% | 0.00% | -689.52% |
| Income Tax Expense | 49.76M | 52.07M | 63.09M | 19.06M | 77.10M | -237.98M | 4.35M | 32.06M | 55.00K | -182.00K | -96.00K | 107.00K | 1.30M | -72.00K | -1.29M | -18.14M | -107.60M | 0.00 | -9.59M | 30.69M | -345.00K | 345.00K | 2.55M | 32.45M | -100.00K | 0.00 |
| Net Income | 207.77M | 182.28M | 231.06M | 111.78M | 321.01M | 690.07M | 154.23M | -70.22M | -169.74M | -268.54M | -244.76M | -147.65M | 75.70M | -92.33M | -135.22M | -162.85M | -86.38M | -101.49M | -84.40M | -137.25M | -94.77M | -86.13M | -71.19M | -75.31M | -18.70M | -15.67M |
| Net Income Ratio | 11.35% | 11.31% | 16.10% | 11.32% | 33.17% | 80.82% | 34.09% | -36.68% | -456.63% | -1,069.42% | -781.03% | -311.16% | 26.14% | -49.90% | -89.10% | -138.18% | -76.13% | -102.86% | -111.11% | -259.65% | -183.88% | -194.33% | -173.60% | -304.18% | -178.10% | -689.52% |
| EPS | 0.65 | 0.57 | 0.73 | 0.36 | 1.06 | 2.32 | 0.52 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.60 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| EPS Diluted | 0.65 | 0.56 | 0.72 | 0.35 | 1.02 | 2.21 | 0.49 | -0.28 | -0.81 | -1.38 | -1.33 | -0.92 | 0.58 | -0.85 | -1.26 | -1.54 | -0.87 | -1.17 | -1.07 | -1.89 | -1.45 | -1.52 | -1.53 | -2.43 | -4.60 | -7.88 |
| Weighted Avg Shares Out | 318.15M | 321.53M | 314.88M | 308.27M | 302.58M | 297.89M | 293.59M | 250.53M | 209.23M | 194.30M | 184.03M | 160.14M | 126.02M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
| Weighted Avg Shares Out (Dil) | 321.46M | 324.56M | 322.36M | 318.00M | 315.01M | 312.80M | 312.00M | 250.53M | 209.23M | 194.30M | 184.06M | 160.14M | 130.48M | 108.52M | 107.07M | 105.50M | 99.15M | 86.60M | 78.81M | 72.50M | 65.39M | 56.62M | 46.49M | 31.03M | 4.07M | 1.99M |
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
3 Reasons Growth Investors Will Love Exelixis (EXEL)
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Source: https://incomestatements.info
Category: Stock Reports